← Leaderboards
Thomas J. McCown
Univ Of North Carolina Chapel Hill
$7,445,525
Attributed
$7,738,840
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $919.1K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,738,840 · 6
By mechanism
R01$6,996,407 · 4
R21$742,433 · 2
Top collaborators
- Steven J Gray1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Richard J Samulski$19,583,832
- Steven J Gray$7,162,149
- Suk-Won Jin$3,875,368
- Natalie McCarter Bowman$3,960,961
- Chengwen Li$10,504,911
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyAdeno-Associated Viral VectorVectorIn VivoEpilepsyNeuronsRattusExhibitsCapsidGalaninGenesDependovirusSerotypingMutantSeizuresSiteAttenuatedKainic AcidCellular TropismAntiepileptic AgentsGene ExpressionExcisionOperative Surgical ProceduresPeripheral
Grant awards (24)
AAV capsid-promoter interactions determines CNS cell selective gene expression in vivo$388,750
R01 · FY2025 · NS · contact PI
AAV capsid-promoter interactions determines CNS cell selective gene expression in vivo$377,088
R01 · FY2024 · NS · contact PI
Optimizing a Novel AAV Vector to Selectively Influence Seizure Networks In Vivo$427,625
R21 · FY2023 · NS · contact PI
AAV capsid-promoter interactions determines CNS cell selective gene expression in vivo$388,750
R01 · FY2023 · NS · contact PI
AAV capsid-promoter interactions determines CNS cell selective gene expression in vivo$388,750
R01 · FY2022 · NS · contact PI
AAV capsid-promoter interactions determines CNS cell selective gene expression in vivo$388,750
R01 · FY2021 · NS · contact PI
Directed Evolution of Novel AAV Capsids for Global CNS Delivery in Rodents and Primates$586,631
R01 · FY2017 · NS
Development of Intravenous AAV Vectors for Intractable Epilepsy$332,500
R01 · FY2017 · NS · contact PI
Development of Intravenous AAV Vectors for Intractable Epilepsy$332,500
R01 · FY2016 · NS · contact PI
Development of Intravenous AAV Vectors for Intractable Epilepsy$332,500
R01 · FY2015 · NS · contact PI
Development of Intravenous AAV Vectors for Intractable Epilepsy$329,176
R01 · FY2014 · NS · contact PI
Development of Intravenous AAV Vectors for Intractable Epilepsy$332,500
R01 · FY2013 · NS · contact PI
Gene Therapy and Seizures$310,530
R01 · FY2011 · NS · contact PI
Gene Therapy and Seizures$313,699
R01 · FY2010 · NS · contact PI
Gene Therapy and Seizures$316,867
R01 · FY2009 · NS · contact PI
Gene Therapy and Seizures$316,867
R01 · FY2008 · NS · contact PI
Directed Evolution of Adeno-Associated Virus Vectors for Seizure Gene Therapy$157,404
R21 · FY2008 · NS · contact PI
Directed Evolution of Adeno-Associated Virus Vectors for Seizure Gene Therapy$157,404
R21 · FY2007 · NS · contact PI
Gene Therapy and Seizures$276,450
R01 · FY2005 · NS
Gene Therapy and Seizures$276,450
R01 · FY2004 · NS
Gene Therapy and Seizures$276,450
R01 · FY2003 · NS
Gene Therapy and Seizures$300,200
R01 · FY2002 · NS
GENE THERAPY AND SEIZURES$218,678
R01 · FY2001 · NS
GENE THERAPY AND SEIZURES$212,321
R01 · FY2000 · NS